Amgen meets analyst estimates, but shares drop on Q2 earnings decline
Amgen’s revenues climbed 6 percent in the second quarter, to $6.2 billion, despite the COVID-19 pandemic limiting hospital and physician operations and putting a hitch in diagnosis and treatment for many patients. Amgen’s earnings, announced July 28, met average analyst estimates. However, a 17 percent overall decline in net income for the Thousand Oaks biotech Read More →
Oxnard’s Cure makes $20M buy of CBD firm
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
American Riviera Bank earnings tick up in Q2
American Riviera Bank saw a slight rise in its unaudited net income in the second quarter, but the Santa Barbara-based bank is still facing a decreased net income for the year as it prepares for loan losses. The bank’s unaudited net income in the second quarter of 2020 was $1.56 million, up from $1.51 million Read More →
Teledyne stock climbs as Q2 earnings beat analyst estimates
Second-quarter sales for Thousand Oaks-based Teledyne Technologies dipped 5 percent to $743.3 million, and net income beat analyst estimates, sending the stock up 2.5 percent in early trading. Net income fell around 10 percent compared to the previous year’s second quarter to $93.7 million, or $2.48 per share, squarely beating analyst predictions of around $2 Read More →
Crimson, contractor will pay $1.6M to settle claims over 2016 Ventura oil spill
The companies responsible for a 2016 oil spill in the Ventura foothills will pay the state and county $1.6 million in a legal settlement announced July 21. Crimson Pipeline agreed to pay $1.3 million in civil penalties and costs, according to a news release from Ventura County District Attorney Greg Totten’s office. Crimson’s contractor, CD Read More →
Amgen puts $421M into BeiGene
Thousand Oaks biotech giant Amgen has upped its investment in Chinese oncology research firm BeiGene by $421 million. Amgen’s new investment, announced July 13, will allow the company maintain its ownership interest in BeiGene at 20.3 percent following a direct offering by the Chinese firm. Amgen shares rose more than 1 percent following the news Read More →
Movegreen makes LA, Orange County acquisitions
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
